Dova’s Doptelet OK’d in Europe for low blood platelets; shares up 4% premarket

Thinly traded micro cap Dova Pharmaceuticals (NASDAQ:DOVA) is up 4% premarket on light volume on the heels of European Commission approval of DOPTELET (avatrombopag) for severe thrombocytopenia (low blood platelets) in adults with chronic liver disease who are scheduled to undergo an invasive procedure.

The FDA approved it for the indication in May 2018.

https://seekingalpha.com/news/3473539-dovas-doptelet-okd-europe-low-blood-platelets-shares-4-percent-premarket